Kraig Biocraft Laboratories, Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 12, 2021 and accepted by EDGAR at Aug 12, 2021, 16:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $0 | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $0 | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2021-04-01 to 2021-06-30 | $44.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $132.5k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$705.2k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$2.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | −$3.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-04-01 to 2021-06-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2021-01-01 to 2021-06-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | −$966.8k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $5.1k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-06-30 | $3.7m | us-gaap:Cash |
| Current assets | At period end2021-06-30 | $3.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $4.1m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $8.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $9.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-06-30 | −$5.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-21-019530. Last ingested by Listed: Oct 24, 2026, 15:09 ET. Listed shows no prices and gives no investment advice.